Xiaofang Pharmaceutical said at the 2026 semi-annual performance briefing that the company's future profit growth will mainly rely on two core drivers: breakthroughs in innovative drug research and development and omnichannel sales volume, while benefiting from the long-term expansion of the topical drug market. The company has long been optimistic about the home-use topical medication circuit. Aging and health consumption upgrades have brought stable demand, and the industry space is broad. The company will continue to cultivate its main business, promote product innovation, and seize industry opportunities.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.